Posts tagged Andrew Fein
HCW starts Concert at buy

H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24.

Read More
HCW ups SteadyMed price target to $15

H.C. Wainwright raised its price target for SteadyMed (NASDAQ:STDY) to $15 from $10 after the Patent Trial and Appeal Board ruled in favor of SteadyMed in an inter partes review (IPR) proceeding against United Therapeutics’ 8,497393 patent, finding all 22 claims in the patent unpatentable. The stock closed at $5.80 on March 31.

Read More
HCW starts Bellerophon Therapeutics at buy

H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20.

Read More
HCW starts Anthera Pharma at buy

H.C. Wainwright initiated coverage of Anthera Pharmaceuticals (NASDAQ:ANTH) with a “buy” rating and $10 price target. The stock closed at $3.38 on Thursday.

“We believe that at this time Anthera’s pipeline and value proposition has bifurcated into two components of very different risk/reward,” writes analyst Andrew Fein.

Read More
HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday.

“Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively low clinical and regulatory risk,” writes analyst Andrew Fein.

Read More
HCW starts Windtree Therapeutics at buy

H.C. Wainwright has launched coverage of Windtree Therapeutics (NASDAQ:WINT) with a “buy” rating and $8 price target, ahead of study readouts on tap for the next 12 months. The stock closed at $3.03 on Thursday.

“We believe that the company’s investigational drug/device combination, Aerosurf, which aims to deliver aerosolized surfactant to neonates with respiratory distress syndrome (RDS), is competitively positioned to be the first deliverable, noninvasive surfactant therapy in an otherwise under saturated market,” writes analyst Andrew Fein.

Read More
HCW starts Actinium Pharma at buy

H.C. Wainwright has launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with a “buy” rating and a price target of $8. The stock closed at $1.98 on Friday.

"We believe that due to a long history of pivotal failures on top of a scarcity of treatment options, AML is likely to start enjoying some regulatory slack over the next few years, with Actinium well-positioned for value with two pedigreed assets tackling two different stages of the disease,” writes analyst Andrew Fein.

Read More